Urothelial carcinoma (UC) is found primarily in the bladder and is a lethal malignancy worldwide with a poor prognosis. There are currently various methods of treatment that are dependent on the stage of the disease and whether the tumor is invasive or non-invasive. The most standard and optimal treatment for UC of the distal ureter (DUUC) is radical nephroureterectomy with bladder cuff excision. Partial ureterectomy remains an option in patients who have a solitary kidney or bilateral ureteral carcinoma or chronic renal insufficiency. Patients with low risk non-muscle invasive bladder cancer (NMIBC) are treated with transurethral resection of bladder tumor compared to patients with high risk NMIBC, in which cystectomy or intravesical induction therapy combined with chemotherapy is recommended. Patients can also receive drug therapies including methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), dose dense MVAC, and lastly gemcitabine with cisplatin as a standard of treatment.
Although there has been significant development towards the treatment for UC patients, metastatic UC still has a poor prognosis with an estimated median survival of up to 15 months. Studies have found molecular mechanisms may be responsible for the resistance to therapies and treatment. For example, studies have identified UC patients to have different levels of expression of various proteins including matrix metalloproteinase-7 which has been found to impact the prognosis after chemotherapy. Further studies have also shown long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) to impact UC proliferation and resistance to chemotherapy. Therefore, further studies are required to identify how molecular mechanisms impact UC treatment and therapies.
The aim of this Research Topic is to explore how the various surgical treatments affect urothelial carcinoma patients and the impact it has on the survival rate and overall prognosis. Additionally, we would like to explore how molecular mechanisms and lifestyle factors such as smoking and other health conditions such as diabetes also impact the therapies and treatment of UC patients.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Urothelial carcinoma (UC) is found primarily in the bladder and is a lethal malignancy worldwide with a poor prognosis. There are currently various methods of treatment that are dependent on the stage of the disease and whether the tumor is invasive or non-invasive. The most standard and optimal treatment for UC of the distal ureter (DUUC) is radical nephroureterectomy with bladder cuff excision. Partial ureterectomy remains an option in patients who have a solitary kidney or bilateral ureteral carcinoma or chronic renal insufficiency. Patients with low risk non-muscle invasive bladder cancer (NMIBC) are treated with transurethral resection of bladder tumor compared to patients with high risk NMIBC, in which cystectomy or intravesical induction therapy combined with chemotherapy is recommended. Patients can also receive drug therapies including methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), dose dense MVAC, and lastly gemcitabine with cisplatin as a standard of treatment.
Although there has been significant development towards the treatment for UC patients, metastatic UC still has a poor prognosis with an estimated median survival of up to 15 months. Studies have found molecular mechanisms may be responsible for the resistance to therapies and treatment. For example, studies have identified UC patients to have different levels of expression of various proteins including matrix metalloproteinase-7 which has been found to impact the prognosis after chemotherapy. Further studies have also shown long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) to impact UC proliferation and resistance to chemotherapy. Therefore, further studies are required to identify how molecular mechanisms impact UC treatment and therapies.
The aim of this Research Topic is to explore how the various surgical treatments affect urothelial carcinoma patients and the impact it has on the survival rate and overall prognosis. Additionally, we would like to explore how molecular mechanisms and lifestyle factors such as smoking and other health conditions such as diabetes also impact the therapies and treatment of UC patients.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
